Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin

In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bleeding. This study sought to explore the effects o...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American College of Cardiology Vol. 74; no. 12; p. 1519
Main Authors:	Eikelboom, John W, Bosch, Jacqueline J, Connolly, Stuart J, Shestakovska, Olga, Dagenais, Gilles R, Hart, Robert G, Leong, Darryl P, O'Donnell, Martin, Fox, Keith A A, Bhatt, Deepak L, Cairns, John A, Tasto, Christoph, Berkowitz, Scott D, Cook Bruns, Nancy, Muehlhofer, Eva, Diaz, Rafael, Maggioni, Aldo P, Yusuf, Salim
Format:	Journal Article
Language:	English
Published:	United States 24.09.2019
Subjects:	Aged Aspirin - administration & dosage Aspirin - adverse effects Coronary Artery Disease - complications Drug Combinations Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - adverse effects Female Hemorrhage - chemically induced Humans Male Peripheral Arterial Disease - complications Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Rivaroxaban - administration & dosage Rivaroxaban - adverse effects Severity of Illness Index coronary artery disease dual pathway aspirin rivaroxaban bleeding peripheral artery disease
ISSN:	1558-3597, 1558-3597
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!